| Q37734452 | "Targeted" Chemotherapy for Esophageal Cancer |
| Q89623377 | 'Omics Approaches to Explore the Breast Cancer Landscape |
| Q101166804 | A DNA-nanoassembly-based approach to map membrane protein nanoenvironments |
| Q90117982 | A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks |
| Q37694673 | A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity |
| Q89172835 | A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab |
| Q26773907 | Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer |
| Q33608593 | Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes |
| Q64950548 | Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. |
| Q64124307 | Advances in bacterial cancer therapies using synthetic biology |
| Q90029476 | Alternative ORFs and small ORFs: shedding light on the dark proteome |
| Q26797471 | Analysis of different HER-2 mutations in breast cancer progression and drug resistance |
| Q60924652 | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |
| Q54252199 | Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization. |
| Q91845207 | Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines |
| Q90247804 | Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar |
| Q37648136 | Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. |
| Q38694128 | BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model |
| Q104471894 | C-demethylation and 1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethylidene)hydrazinecarboxamide to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide and their applications |
| Q40903579 | Change in CD3ζ-chain expression is an independent predictor of disease status in head and neck cancer patients |
| Q41595482 | Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer |
| Q58803669 | Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer |
| Q92557334 | Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance |
| Q64076747 | Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex |
| Q62495036 | Current Strategies and Applications for Precision Drug Design |
| Q45943585 | Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells. |
| Q41661216 | Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload |
| Q90473436 | Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets |
| Q64955074 | Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways |
| Q92550910 | Discovery and mechanisms of host defense to oncogenesis: targeting the β-defensin-1 peptide as a natural tumor inhibitor |
| Q36312110 | Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models |
| Q41835996 | Driving better and safer HER2-specific CARs for cancer therapy |
| Q93155695 | Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies |
| Q42281218 | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers |
| Q26746909 | Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy |
| Q90266694 | Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7 |
| Q54994574 | FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis. |
| Q91980872 | Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
| Q37377544 | Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma |
| Q90393213 | Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab |
| Q64063349 | HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer |
| Q47304027 | HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target? |
| Q91728336 | HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis |
| Q37269081 | HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth |
| Q41934319 | HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers |
| Q47222791 | Hitting the Target: How T Cells Detect and Eliminate Tumors |
| Q99408079 | Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer |
| Q41660817 | Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells |
| Q90211923 | Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro |
| Q37045824 | Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification |
| Q37221158 | Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study |
| Q37013995 | Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma |
| Q35842236 | Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role |
| Q90469063 | Impact of Molybdenum Compounds as Anticancer Agents |
| Q42070603 | Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer |
| Q55264153 | Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma. |
| Q99565418 | Investigation of HER-2 Expression an Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients |
| Q30250289 | Is the false-positive rate in mammography in North America too high? |
| Q47160829 | Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. |
| Q38569109 | Membrane microparticles: shedding new light into cancer cell communication. |
| Q49375694 | Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report |
| Q92890127 | NDRG1 suppresses vasculogenic mimicry and tumor aggressiveness in gastric carcinoma |
| Q98167111 | Nanoparticulate RNA delivery systems in cancer |
| Q50201250 | Neratinib: First Global Approval |
| Q47221234 | New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness |
| Q48924057 | Non-fluorescent quantification of single mRNA with transient absorption microscopy. |
| Q92384079 | Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer |
| Q38845078 | Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity |
| Q89622510 | Ovarian Cancer Targeted Theranostics |
| Q47281580 | Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology? |
| Q90482989 | Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade |
| Q100490609 | Overview of current targeted therapy in gallbladder cancer |
| Q90987627 | PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers |
| Q36295013 | PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas |
| Q98177661 | Peptide Vaccine Combined Adjuvants Modulate Anti-tumor Effects of Radiation in Glioblastoma Mouse Model |
| Q61810424 | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| Q36344901 | Polymeric oncolytic adenovirus for cancer gene therapy |
| Q26775315 | Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives |
| Q55175195 | Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia. |
| Q97094411 | Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via FUT8 knockout CHO-S cells |
| Q91984696 | Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation |
| Q58601833 | Prognostic value of ErbB2/HER2 in human meningiomas |
| Q64891425 | Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. |
| Q40975738 | Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization. |
| Q64056483 | Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib |
| Q36583265 | Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy. |
| Q57162471 | RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine |
| Q89541984 | Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib |
| Q38662712 | Review: circulating tumor cells in the practice of breast cancer oncology. |
| Q38704805 | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression |
| Q64288884 | Screening of potential phytocompounds from Euclea crispa (Thunb.) leaves targeting human epidermal growth factor receptor 2 (HER2) signaling pathway |
| Q97094559 | Silica-based organic-inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery |
| Q57477210 | Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2 |
| Q51708755 | Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. |
| Q91637215 | Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer |
| Q58798280 | Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody |
| Q48042475 | Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants |
| Q93006248 | Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy |
| Q52346962 | Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach. |
| Q30835291 | Superresolution Imaging of Clinical Formalin Fixed Paraffin Embedded Breast Cancer with Single Molecule Localization Microscopy |
| Q47190264 | Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review |
| Q33822560 | Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines |
| Q96950520 | Systems biology comprehensive analysis on breast cancer for identification of key gene modules and genes associated with TNM-based clinical stages |
| Q55210424 | Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles. |
| Q26781278 | Targeting RTK Signaling Pathways in Cancer |
| Q91634586 | Targeting fusions for improved outcomes in oncology treatment |
| Q39390640 | Targeting the mTOR pathway in breast cancer |
| Q47411655 | The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study |
| Q35687706 | The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas |
| Q95841155 | The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review |
| Q47167746 | The crossroads of breast cancer progression: insights into the modulation of major signaling pathways |
| Q49887908 | The role of RICTOR downstream of receptor tyrosine kinase in cancers. |
| Q95661084 | The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q93167098 | Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine |
| Q28069898 | Tumour biomarkers: homeostasis as a novel prognostic indicator |
| Q37743486 | mTOR function and therapeutic targeting in breast cancer |